臨床検査55巻5号

2011年05月発行

今月の主題 癌幹細胞と検査医学 各論 〈検査〉

癌幹細胞マーカー

著者： 山崎裕人¹ 森本幾夫¹

所属機関： ¹東京大学医科学研究所免疫病態分野

ページ範囲：P.458 - P.463

癌幹細胞の分離・同定に用いられるマーカーは大きく分けて，細胞表面抗原であるCDマーカーと，細胞内の代謝活性を利用した方法とに分けられる．固形癌におけるCDマーカーには，CD44，CD133などの多くのタイプの癌に共通のマーカーと，組織特異的なマーカーに分けられる．代謝活性を指標にしたマーカーは，ヒト以外の動物細胞でも応用可能で，ヘキスト色素の排出能を指標にしたSide population法と，ALDH1酵素活性を検出する方法があり，いずれもフローサイトメーターで検出できる．

参考文献

1) 山崎裕人，森本幾夫：血液腫瘍における癌幹細胞．病理と臨床　25：325-330，2007

2) Lapidot T, Sirard C, Vormoor J, et al:A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature　367：645-648，1994

3) Klonisch T, Wiechec E, Hombach-Klonisch S, et al:Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med　14：450-460，2008

4) Visvader JE, Lindeman GJ:Cancer stem cells in solid tumours:accumulating evidence and unresolved questions. Nat Rev Cancer　8：755-768，2008

5) Frank NY, Schatton T, Frank MH:The therapeutic promise of the cancer stem cell concept. J Clin Invest　120：41-50，2010

cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell　6：603-615，2010

7) Moserle L, Ghisi M, Amadori A, et al:Side population and cancer stem cells:Therapeutic implications. Cancer Lett　288：1-9，2010

8) Nishii T, Yashiro M, Shinto O, et al:Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci　100：1397-1402，2009

9) Ho MM, Ng AV, Lam S, et al:Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res　67：4827-4833，2007

10) Murase M, Kano M, Tsukahara T, et al:Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer　101：1425-1432，2009

11) Wu C, Wei Q, Utomo V, et al:Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res　67：8216-8222，2007

12) Rasheed ZA, Yang J, Wang Q, et al:Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Nat Can Inst　102：340-351，2010

13) Jiang F, Qiu Q, Khanna A, et al:Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res　7：330-338，2009

14) Lathia JD, Gallagher J, Heddleston JM, et al:Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell　6：421-432，2010

15) Haraguchi N, Ishii H, Mimori K, et al:CD13 is a therapeutic target in human liver cancer stem cells. J Clin Inves　120：3326-3339，2010

16) Takaishi S, Okumura T, Tu S, et al:Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells　27：1006-1020，2009

17) Fang D, Nguyen TK, Leishear K, et al:A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res　65：9328-9337，2005

18) Boiko AD, Razorenova OV, van de Rijn M, et al:Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature　466：133-137，2010

19) Curley MD, Therrien VA, Cummings CL, et al:CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells　27：2875-2883，2009

cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene　29：2672-2680，2010

21) Rutella S, Bonanno G, Procoli A, et al:Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res　15：4299-4311，2009

22) Ghani FI, Yamazaki H, Iwata S, et al:Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun　404：735-742，2011

23) Misaghian N, Ligresti G, Steelman LS, et al:Targeting the leukemic stem cell:the Holy Grail of leukemia therapy. Leukemia　23：25-42，2009

24) Vormoor HJ:Malignant stem cells in childhood acute lymphoblastic leukemia:the stem cell concept revisited. Cell Cycle　8：996-999，2009

25) van Rhenen A, van Dongen GA, Kelder A, et al:The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood　110：2659-2666，2007

26) Nishida H, Yamazaki H, Yamada T, et al:CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells. Biochem Biophys Res Commun　382：57-62，2009

27) Yamazaki H, Nishida H, Iwata S, et al:CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells. Biochem Biophys Res Commun　383：172-177，2009

28) Matsui W, Wang Q, Barber JP, et al:Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res　68：190-197，2008

29) Taussig DC, Pearce DJ, Simpson C, et al:Hematopoietic stem cells express multiple myeloid markers:implications for the origin and targeted therapy of acute myeloid leukemia. Blood　106：4086-4092，2005

30) Majeti R, Chao MP, Alizadeh AA, et al:CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell　138：286-299，2009

31) Kikushige Y, Shima T, Takayanagi S, et al:TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell　7：708-717，2010